USD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$1.12B
Market Cap
-
P/E Ratio
-1.31
EPS
$30.35
52 Week High
$2.82
52 Week Low
HEALTHCARE
Sector
| Field | Value (EUR) |
|---|---|
| Operating Cashflow | -$20M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $1.6M |
| Capital Expenditures | $848K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$955K |
| Cashflow From Financing | -$5.1M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $0 |
| Dividend Payout Common Stock | $0 |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$68M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Nanobiotix SA is a pioneering clinical-stage biotechnology company based in Paris, France, specializing in the development of groundbreaking cancer therapies utilizing its proprietary nanotechnology platform. Committed to improving treatment efficacy and minimizing side effects, the company is advancing a robust pipeline of localized therapies across multiple clinical trial stages. With its innovative approach and strategic partnerships, Nanobiotix is poised to redefine oncology treatment paradigms and enhance patient outcomes on a global scale, positioning itself as a significant player in the fight against cancer.